RxDoctor Payments Data

Bryan Laura, MD

Internal Medicine · Evansville, INNPI 1346227725

Payments from drug & device makers

$533in general payments, 2019–2025

Across 33 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$132
  • Novo Nordisk$123
  • Amgen$81
  • Pfizer$54
  • AbbVie$53
  • Boehringer Ingelheim$24
  • plus $65 from 4 others

What the payments were for

  • Food & beverage$533100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$533 in reported general payments places this provider in the 65th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$172,454
Medicare patients
385
Services billed
5,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$48,418
EliquisApixaban54$48,317
RybelsusSemaglutide15$25,821
JanuviaSitagliptin Phosphate22$24,446
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$23,950
MyrbetriqMirabegron27$20,231
VraylarCariprazine Hcl11$18,433
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$12,543
JardianceEmpagliflozin13$12,528
Breo ElliptaFluticasone/Vilanterol14$5,706
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen291$5,597
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,313
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$4,713
DuleraMometasone/Formoterol13$4,684
Aripiprazole28$3,501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$123$74,23953 claims
PfizerEliquis$54$48,31754 claims
AbbVieVraylar, Synthroid$53$21,44140 claims
Boehringer IngelheimJardiance$24$12,52813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →